Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Peregrine Pharmaceuticals reports results from phase II bavituximab trial

Feb. 14, 2013

ImmunoGen achieves patient enrollment milestone in phase II NORTH trial

Feb. 13, 2013

TG Therapeutics opens expansion cohorts in trial of ublituximab

Feb. 12, 2013

First patient treated in phase I trial of GL-ONC1

Feb. 7, 2013

Seattle Genetics begins two phase I trials of SGN-CD19A

Feb. 7, 2013

Therapeutic cervical cancer vaccine eradicates established tumors in mice

Feb. 7, 2013

Health Canada grants approval to Adcetris for two lymphoma indications

Feb. 4, 2013

Teva Pharmaceutical terminates agreements with CureTech

Feb. 4, 2013

Targovax includes first patient in phase I/II TG-01 study

Feb. 1, 2013

New MAbs described by Oxford BioTherapeutics

Feb. 1, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...